{
  "id": 774641,
  "title": "Earnings call transcript: Kuros Biosciences posts H1 2026 profit on 45% sales gain",
  "url": "https://urgent.news/2026/08/13/earnings-call-transcript-kuros-biosciences-posts-h1-2026-profit-on-45",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-13T14:32:52.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-kuros-biosciences-posts-h1-2026-profit-on-45-sales-gain-93CH-4858475"
  },
  "original_language": "en",
  "account": "Kuros Biosciences announced a first-half profit for 2026, driven by a 45% sales increase. The Swiss medical device maker reported CHF 92.4 million in sales and adjusted EBITDA of CHF 12.5 million, marking a shift from a CHF 2 million loss in the previous year. The stock held steady at $22.96, below its 52-week high of $34.20 but above the low of $17.69.\n\nOrthopedic biologics sales continued to grow rapidly, with direct MagnetOs sales up 46%. The company has treated over 150,000 patients worldwide since launch. Kuros relies heavily on the U.S. market, which accounts for about 95% of revenue. Their gross profit margin of 87% indicates efficiency.\n\nManagement highlighted hospital accounts, surgeon adoption, and strong institutional relationships as key growth drivers. They now work with over 600 hospitals in the U.S., with surgeon utilization at 16% in H1. International sales, though smaller, are growing, with the company seeking 5-10% international revenue in the medium term.\n\nKuros expects revenue to grow about 35% in 2026, and aims to more than double revenue to CHF 300-330 million by 2028. However, analysts forecast earnings per share of $0.31. Kuros is still working to reduce fixed costs and improve margins, with H2 margins expected to face some pressure. The company is now viewed as a \"profitable, high-growth medical technology company.\"",
  "summary": null,
  "key_points": [
    "Kuros Biosciences reports CHF 92.4 million in H1 2026 sales",
    "Orthopedic biologics sales up 46%, treating over 150,000 patients",
    "Company aims to double revenue to CHF 300-330 million by 2028"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}